Abstract:Background: Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide. Because many hepatocellular carcinomas are already unresectable at the time of initial diagnosis, percutaneous tumor ablation has become established in recent decades as a curative therapeutic approach for very early (BCLC 0) and early (BCLC A) HCC. The aim of this paper is to provide a concise overview of the percutaneous local ablative procedures currently in use, based on their technical characteristics as well as clinical relevance, taking into account the current body of studies. Materials and methods: The literature search included all original papers, reviews, and meta-analyses available via MEDLINE and Pubmed on the respective percutaneous ablation procedures; the primary focus was on randomized controlled trials and publications from the last 10 years. Results and conclusions: Radiofrequency ablation (RFA) and microwave ablation (MWA) are well-established procedures that are considered equal to surgical resection in the treatment of stage BCLC 0 and A HCC with a diameter up to 3 cm due to their strong evidence in international and national guidelines. For tumors with a diameter between 3 and 5 cm, the current S3 guidelines recommend a combination of transarterial chemoembolization (TACE) and thermal ablation using RFA or MWA as combination therapy is superior to thermal ablation alone in tumors of this size and shows comparable results to surgical resection in terms of overall survival. Alternative, less frequently employed thermal procedures include cryotherapy (CT) and laser ablation (LA). Non-thermal procedures include irreversible electroporation (IRE), interstitial brachytherapy (IBT), and most recently, electrochemotherapy (ECT). Due to insufficient evidence, these have only been used in individual cases and within the framework of studies. However, the nonthermal methods are a reasonable alternative for ablation of tumors adjacent to large blood vessels and bile ducts because they cause significantly less damage to these structures than thermal ablation methods. With advances in the technology of the respective procedures, increasingly good evidence, and advancements in supportive techniques such as navigation devices and fusion imaging, percutaneous ablation procedures may expand their indications for the treatment of larger and more advanced tumors in the coming years. Key points: · RFA and MWA are considered equal to surgical resection as a first-line therapy for the curative treatment of stage BCLC 0 and A HCCs with a diameter of up to 3 cm.. · For HCCs with a diameter between 3 and 5 cm, a combination of TACE and RFA or MWA is recommended. This combination therapy yields results comparable to those of surgical resection in terms of overall survival.. · Due to insufficient evidence, alternative ablation methods have only been used in individual cases and within the framework of studies. However, nonthermal methods, such as IRE, IBT, and, most recently, ECT, are a reasonable alternative for ablation of HCCs adjacent to large blood vessels and bile ducts because they cause significantly less damage to these structures than thermal ablation methods.. Citation format: · Luerken L, Haimerl M, Doppler M et al. Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma. Fortschr Röntgenstr 2022; 194: 1075 - 1086.

Chemoembolization Plus Ablation: Current Status

Treatment of Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Systemic Therapy

Editorial: Interventional Therapy of Hepatocellular Carcinoma

Embolotherapy in the Management of Hepatocellular Carcinoma.

The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation Against Hepatocellular Carcinoma

Treatment of localized hepatocellular carcinoma: resection vs. ablation vs. radiation

Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status

Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma

Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma

The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy

Meta-analysis of transarterial chemoembolization combined with cryoablation vs transarterial chemoembolization alone for ≥ 5 cm hepatocellular carcinoma

Recent Advances in Tumor Ablation for Hepatocellular Carcinoma

Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study

Update on Embolization Therapies for Hepatocellular Carcinoma

Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review

Percutaneous Thermal Ablation Combined with Simultaneous Transarterial Chemoembolization for Hepatocellular Carcinoma ≤5 Cm

Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?

Recent treatments to Hepatocellular Carcinoma Cancer(HCC): update and outlook

Ablation versus Radiation Segmentectomy for Small Liver Tumors

Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes